Treatment of Guillain-Barré syndrome with interferon-beta.
A
A
Créange
H
H
Lerat
C
C
Meyrignac
J D
JD
Degos
R K
RK
Gherardi
P
P
Cesaro
D000200:Action Potentials / Q000502:physiology; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001342:Autonomic Nervous System Diseases / Q000503:physiopathology; D002169:Campylobacter Infections; D016123:Campylobacter jejuni; D003389:Cranial Nerve Diseases / Q000503:physiopathology; D016207:Cytokines / Q000502:physiology; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D018836:Inflammation Mediators / Q000276:immunology; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018908:Muscle Weakness / Q000503:physiopathology; D009431:Neural Conduction / Q000502:physiology; D010291:Paresis / Q000503:physiopathology; D010523:Peripheral Nervous System Diseases / Q000503:physiopathology; D011129:Polyradiculoneuropathy / Q000276:immunology / Q000382:microbiology / Q000503:physiopathology / Q000628:therapy*; D012021:Reflex, Abnormal; D012678:Sensation Disorders / Q000503:physiopathology
D000276:Adjuvants, Immunologic; D016207:Cytokines; D018836:Inflammation Mediators; D016899:Interferon-beta